Market News / Story
Key facts: Tempus AI (TEM) Q2 $382.5M; Oncology Model for AstraZeneca
·
Tempus AI (TEM) reported Q2 2026 revenue of $382.5M: $289.3M diagnostics and $93.2M data & applications, showing the company’s segment revenue split for the quarter. Tempus AI (TEM) delivered its first oncology foundational model to AstraZeneca under their collaboration. The announcement notes the transfer but gives no pricing, release timeline, scale, or terms. This is an AI-generated summary and may contain inaccuracies. Please verify any important information with…